Last reviewed · How we verify

Atherosclerosis — Treatment Landscape & Competitive Intelligence

Atherosclerosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atherosclerosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Praluent ALIROCUMAB Sanofi PCSK9 Inhibitor [EPC] Proprotein convertase subtilisin/kexin type 9 2015-01-01
Colcrys COLCHICINE Scilex Pharms Alkaloid [EPC] Serine/threonine-protein kinase pim-1 1961-01-01
Praluent Praluent Regeneron Pharmaceuticals Proprotein convertase subtilisin/kexin type 9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Regeneron Pharmaceuticals · 1 drug in Atherosclerosis
  2. Sanofi · 1 drug in Atherosclerosis
  3. Scilex Pharms · 1 drug in Atherosclerosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atherosclerosis:

Cite this brief

Drug Landscape (2026). Atherosclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atherosclerosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing